First Nintedanib Clinical Trial For Breast Cancer From CNIO is Successful

First Nintedanib Clinical Trial For Breast Cancer From CNIO is Successful
NintedanibPositive results from the Spanish National Cancer Research Centre (CNIO)'s first Phase 1 clinical trial of nintedanib may advance the therapeutic forward in studies to treat HER-2-negative breast cancer. A combination of nintedanib and standard chemotherapy (paclitaxel) provided remission to 50% of patients with the most common type of breast cancer who were treated with the joint therapy. "The drug combination of paclitaxel and nintedanib has turned out to be a complete success, given that it is proved to be safe and that the pathologic complete response [rate of complete recovery] was 50%, which doubles the response compared to patients treated with standard therapy with paclitaxel," said Miguel Ángel Quintela, head of CNIO's Breast Cancer Clinical Research Unit, in a news release from CNIO. These and other data were published in British Journal of Cancer under the title, "Phase I Clinical Trial of Nintedanib Plus Paclitaxel in Early HER-2-Negative Breast Cancer." It was found that full-dose intensity was achievable, and the recommended dose to move forward to phase 2 trials is 150 mg. The toxic limi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.